FDA Approves Combo Tx for Intermediate, Poor-Risk Advanced Kidney Cancer
The approvals for nivolumab and ipilimumab were based on CheckMate 214, a randomized open-label trial.
Renal Cell Carcinoma
Cabometyx Approved as First-Line Tx for Advanced Renal Cell Carcinoma
Approval provides for treatment in the first-line setting.
Sutent Approved for Patients at High Risk of Recurrent RCC
Sutent was first approved in 2006 for the treatment of certain patients with gastrointestinal stromal tumors and advanced renal cell carcinoma.
